FATIMA SATTAR: Open Payments
NPI 1184087967 · LANCASTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$615 in 28 payments from 9 companies in 2025. Trend: 2023 $1,020 · 2024 $591 · 2025 $615
Food & beverage: $615
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $151 |
| E.R. Squibb & Sons, L.L.C. | 3 | $150 |
| Otsuka America Pharmaceutical, Inc. | 3 | $80 |
| Neurocrine BioSciences, Inc. | 3 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $57 |
| Alkermes, Inc. | 2 | $48 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: COBENFY, UZEDY, INGREZZA, CAPLYTA, ABILIFY ASIMTUFII, REXULTI, AUSTEDO XR, ARISTADA.
Industry payments across PA — which companies pay providers there.
